Citation: Tb. Larsen et al., EFFECT OF ANTICOAGULANT-THERAPY ON THE HYPERCOAGULABLE STATE IN PATIENTS CARRYING THE FACTOR-V ARG506GLN MUTATION, Thrombosis research, 92(4), 1998, pp. 157-162
Authors:
BRANDSLUND I
DAHLERERIKSEN BS
LASSEN JF
DAHLERERIKSEN K
LARSEN TB
Citation: I. Brandslund et al., CHANGE FROM PHENPROCOUMON TO WARFARIN - SCHEME AND PROGRAM FOR MONITORING AND DOSE-ADJUSTMENTS, Thrombosis and haemostasis, 1997, pp. 2865-2865
Authors:
LASSEN JF
DAHLERERIKSEN BS
DAHLERERIKSEN K
LARSEN TB
HUSTED SE
BRANDSLUND I
Citation: Jf. Lassen et al., EFFECT OF CHANGE FROM PHENPROCOUMON TO WARFARIN ON MARKERS OF COAGULATION AND FIBRINOLYSIS, Thrombosis and haemostasis, 1997, pp. 2885-2885
Authors:
DAHLERERIKSEN BS
LASSEN JF
LUND ED
LAURITZEN T
BRANDSLUND I
Citation: Bs. Dahlereriksen et al., C-REACTIVE PROTEIN IN GENERAL-PRACTICE - HOW COMMONLY IS IT USED AND WHY, Scandinavian journal of primary health care, 15(1), 1997, pp. 35-38
Authors:
DAHLERERIKSEN BS
LASSEN JF
PETERSEN PH
LUND ED
LAURITZEN T
BRANDSLUND I
Citation: Bs. Dahlereriksen et al., EVALUATION OF A NEAR-PATIENT TEST FOR C-REACTIVE PROTEIN USED IN DAILY ROUTINE IN PRIMARY HEALTH-CARE BY USE OF DIFFERENCE PLOTS, Clinical chemistry, 43(11), 1997, pp. 2064-2075